Delilah Alvarado

Under the proposed deal, the PE firm would take a controlling 50% stake in Sanofi’s Opella unit, with state-owned Bpifrance taking a minority 2% position.

The shot, which Pfizer sells as Abrysvo, is now approved in adults aged 18 to 59 years old who are at increased risk of disease. Dive Brief:

Sanofi and partner AstraZeneca recently increased production capacity for their RSV antibody shot, sales of which jumped during the third quarter.

New guidelines and the timing of COVID vaccinations impacted uptake of Abrysvo this year, according to a company executive.

The British pharma’s experience during the third quarter mirrored that of rival Pfizer, which also reported lower sales of its competing RSV shot.

The news led to a stock surge on expectations that forthcoming data for the company’s experimental gene therapy for Rett syndrome may turn out positive.

After Kalaris and AlloVir combine, the new company will have about $100 million to advance a treatment for age-related macular degeneration.

After an investigation, the agency concluded that a case of muscle weakness in one of Novavax’s trials was actually ALS and unrelated to vaccination.

At an event hosted by BioPharma Dive, drugmaker executives and investors discussed the importance of focus, smart spending and maintaining lines of sight to the clinic.

Revuforj is the first so-called menin inhibitor cleared in the U.S., securing FDA approval for use in adults and certain pediatric patients with an aggressive form of acute leukemia.